HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity

Stopped early · Phase 1

Conditions studied: Chronic Hepatitis C

In brief

Objective: The goal is to improve peginterferon sensitivity in previous poor responders. "Sensitivity" here means the host's ability to kill more HCV. Design: Twenty poor responders to prior PIFN/RBV will be given 48 weeks of statin monotherapy. Veterans and civilians between the ages of 18 and 70 are eligible.

Key facts

Study ID

NCT01377909

Run by

Bader, Ted, M.D.

People needed

20

Starts

2012-03-01

Expected to finish

2013-08-01

Last updated by the study team

2013-08-22

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hepatitis C positive by HCV RNA within 180 days. - No anti-HCV medicine within 30 days of screening

You may not qualify if…

• decompensated liver disease
• severe cardiac disease (ejection fraction < 20% or uncontrolled angina)
• unexplained muscle pain at time of screening
• pregnancy
• renal insufficiency (creatine clearance < 50 ml/min)

Where it is running

• Veterans Administration Medical Center (VAMC) — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.